医学通信公司
期刊
会议
图书
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1540)医学通信公司
摘要:Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1540)医学通信公司
摘要:View the Comparison Table: Some Nonopioid Analgesics for Pain
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1539)医学通信公司
摘要:The FDA has approved a two-dose hepatitis B virus (HBV) vaccine (Heplisav-B – Dynavax) for use in adults ≥18 years old. The three other HBV vaccines marketed in the US are usually administered in 3 doses. Engerix-B and Recombivax HB are licensed for use in persons of all age...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1539)医学通信公司
摘要:The FDA has approved semaglutide (Ozempic – Novo Nordisk), a long-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-weekly treatment of adults with type 2 diabetes. It is the sixth GLP-1 receptor agonist to be approved in the US.
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1539)医学通信公司
摘要:A reader asked whether healthcare providers should avoid prescribing the angiotensin receptor blocker (ARB) olmesartan medoxomil (Benicar, and others) because it can cause severe GI adverse effects.In 2013, the FDA warned that olmesartan can cause sprue-like enteropathy, a condit...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1539)医学通信公司
摘要:The FDA has approved an oral powder formulation of the amino acid L-glutamine (Endari – Emmaus) to reduce the acute complications of sickle cell disease in patients ≥5 years old. Endari is only the second drug to be approved for use in sickle cell disease; the antimetabolite...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1539)医学通信公司
摘要:The FDA has approved the oral tyrosine kinase inhibitor neratinib (Nerlynx – Puma Biotechnology) for extended adjuvant treatment of adults with early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following adjuvant trastuzumab (Herceptin)-bas...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1539)医学通信公司
摘要:The FDA has warned that the IV emulsion formulation of the substance P/neurokinin 1 (NK1) receptor antagonist rolapitant (Varubi) has been associated in postmarketing reports with serious hypersensitivity reactions including anaphylaxis and anaphylactic shock.1 Rolapitant wa...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1538)医学通信公司
摘要:View the Comparison Table: Drugs for GERD and Peptic Ulcer Disease
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2018, Vol.60 (1538)医学通信公司
摘要:Gastroesophageal reflux disease (GERD) is the most frequent GI condition encountered in the outpatient setting; it affects about 20% of the US population. Heartburn and regurgitation are the classic symptoms of GERD.

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×